Condensed Consolidated Balance Sheets (USD $) In Thousands	Sep. 30, 2011	Dec. 31, 2010
Current assets
Cash and cash equivalents	$ 220,461	$ 235,136
Receivables, less allowance for doubtful accounts of $5,728 at September 30, 2011 and $5,322 at December 31, 2010	258,346	213,553
Inventories - net	271,617	196,546
Other current assets	54,882	47,523
Total current assets	805,306	692,758
Property, plant and equipment - net	219,702	188,562
Goodwill	1,441,640	1,207,001	[1]
Intangible assets - net	393,947	281,392
Other noncurrent assets	33,133	11,982
Total assets	2,893,728	2,381,695
Current liabilities
Trade accounts payable	119,738	104,055
Accrued expenses	173,854	117,879
Current portion of long term debt and short term borrowings	85,395	119,445
Dividends payable	14,172	12,289
Total current liabilities	393,159	353,668
Long-term borrowings	733,204	408,450
Deferred income taxes	166,325	148,534
Other noncurrent liabilities	95,619	95,383
Total liabilities	1,388,307	1,006,035
Commitments and contingencies
Preferred stock:
Authorized: 5,000,000 shares, $.01 per share par value; Issued: None
Common stock:
Authorized: 150,000,000 shares, $.01 per share par value; Issued: 85,897,983 shares at September 30, 2011 and 84,636,668 shares at December 31, 2010	859	846
Additional paid-in capital	485,673	441,271
Retained earnings	1,109,168	1,005,040
Treasury stock at cost: 2,730,385 shares at September 30, 2011 and 2,566,985 shares at December 31, 2010	(64,626)	(58,788)
Accumulated other comprehensive loss	(25,653)	(12,709)
Total shareholders' equity	1,505,421	1,375,660
Total liabilities and shareholders' equity	$ 2,893,728	$ 2,381,695

[1] Revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.